# A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients.

> **NCT00605345** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 71 (actual)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** Darbepoetin alfa
- **DRUG:** methoxy polyethylene glycol-epoetin beta [Mircera]

## Key facts

- **NCT ID:** NCT00605345
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2016-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00605345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00605345, "A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00605345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*